1,063 reports of this reaction
1.5% of all DONEPEZIL HYDROCHLORIDE reports
#16 most reported adverse reaction
DEMENTIA is the #16 most commonly reported adverse reaction for DONEPEZIL HYDROCHLORIDE, manufactured by Camber Pharmaceuticals, Inc.. There are 1,063 FDA adverse event reports linking DONEPEZIL HYDROCHLORIDE to DEMENTIA. This represents approximately 1.5% of all 69,498 adverse event reports for this drug.
DONEPEZIL HYDROCHLORIDE has an overall safety score of 82 out of 100. Patients taking DONEPEZIL HYDROCHLORIDE who experience dementia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEMENTIA is a less commonly reported adverse event for DONEPEZIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dementia, the following adverse reactions have been reported for DONEPEZIL HYDROCHLORIDE:
The following drugs have also been linked to dementia in FDA adverse event reports:
DEMENTIA has been reported as an adverse event in 1,063 FDA reports for DONEPEZIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEMENTIA accounts for approximately 1.5% of all adverse event reports for DONEPEZIL HYDROCHLORIDE, making it a notable side effect.
If you experience dementia while taking DONEPEZIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.